Cluster for the development of new nucleic acid-based therapies C-NATM

The "Cluster for Nucleic Acid Therapeutics Munich" (C-NATM), an innovation network of science and industry, will receive annual funding of five million euros from the federal government, and partly also from the Free State of Bavaria and participating companies, starting in 2023. If the interim evaluation is successful, the duration will be nine years. The spokespersons of the consortium are Professor Thomas Carell, head of the Institute of Chemical Epigenetics at LMU, a renowned RNA chemist, and Professor Stefan Engelhardt, director of the Institute of Pharmacology and Toxicology at the Technical University of Munich (TUM), who specializes in RNA-based therapies. In addition to various disciplines from LMU and TUM, researchers from other research institutions as well as experts from pharmaceutical companies and start-ups from the region are involved.

www.clusters4future.de/die-zukunftscluster/die-zukunftscluster-der-zweiten-wettbewerbsrunde/cnatm